Monopar Therapeutics Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Monopar Therapeutics Inc. (MNPR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $55.08 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $54.28, a 72.59% increase year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $31.45, a 9150.00% increase year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.34, a 89.17% decline year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.14, a 11.74% increase year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $40.55, a 1085.67% increase from fiscal 2024.
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $3.42, a 78.24% decline from fiscal 2023.
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $15.72, a 455.48% increase from fiscal 2022.
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $2.83, a 54.86% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $55.08 10-Q · filed 2026-08-12 | ||||
| 2026-03-31 | $54.28 10-Q · filed 2026-05-14 | ||||
| 2025-12-31 | $40.55 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | $32.31 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | $31.50 10-Q · filed 2025-08-12 | ||||
| 2025-03-31 | $31.45 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | $3.42 10-K · filed 2026-03-27 | ||||
| 2024-09-30 | $3.42 10-Q · filed 2024-11-08 | ||||
| 2024-06-30 | $0.60 10-Q · filed 2024-08-09 | ||||
| 2024-03-31 | $0.34 10-Q · filed 2024-05-09 | ||||
| 2023-12-31 | $15.72 10-K · filed 2025-03-31 | $3.14 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $3.14 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $3.14 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | $3.14 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | $2.83 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $2.80 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | $2.80 10-Q · filed 2022-08-11 | ||||
| 2022-03-31 | $2.81 10-Q · filed 2022-05-12 | ||||
| 2021-12-31 | $6.27 10-K · filed 2023-03-23 | ||||
| 2021-09-30 | $6.29 10-Q · filed 2021-11-12 | ||||
| 2021-06-30 | $6.54 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | $6.93 10-Q · filed 2021-05-13 | ||||
| 2020-12-31 | $14.13 10-K · filed 2022-03-24 | ||||
| 2020-09-30 | $14.08 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | $14.42 10-Q · filed 2020-08-06 | ||||
| 2020-03-31 | $14.55 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | $0.00 10-Q · filed 2020-11-12 | ||||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-12 | ||||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 | ||||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-10 | ||||
| 2018-12-31 | $6.00 10-K · filed 2020-03-27 | ||||
| 2018-09-30 | $6.00 10-Q · filed 2018-11-09 | ||||
| 2018-06-30 | $6.00 10-Q · filed 2018-08-09 | ||||
| 2018-03-31 | $6.00 10-Q · filed 2018-05-11 | ||||
| 2017-12-31 | $1.63 10-K · filed 2019-02-26 | ||||
| 2017-03-31 | $1.63 10-Q · filed 2018-05-11 | ||||
| 2016-12-31 | $0.00 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |